Aclaris Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Our proprietary KINect drug discovery platform, combined with our integrated discovery approach for small and large molecules, allows us to identify and advance product candidates designed for superior target affinity, specificity, and potency. We aim to identify and complete transactions with third-party partners to further develop, obtain marketing approval for, and/or commercialize our novel product candidates. We are dedicated to developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. Our approach includes leveraging our discovery, research, and development expertise, which encompasses state-of-the-art capabilities in small molecule and antibody development, including cell and molecular biology, biochemistry, enzymology, biomarker development, immunology, translational research, in vivo efficacy models, structure-based drug design ("SBDD"), and bioanalytical, computational, and medicinal chemistry. Our team also has broad experience in clinical development and strategy across atopic, respiratory, inflammatory, and immunologic diseases. We also develop innovative biologic product candidates targeting validated pathways, advancing biologics programs comprising monoclonal and multispecific antibodies targeting well-characterized pathways in immuno-inflammatory diseases. Our biologics pipeline includes bosakitug (ATI-045), an anti-thymic stromal lymphopoietin ("TSLP") monoclonal antibody, which has unique differentiation demonstrated by its low dissociation rate, long residence time, and high potency. TSLP is a master regulator of type 2 ("Th2") immune responses and a broadly active key mediator in various inflammatory conditions.